1st Dec 2020 20:38
Frontier IP Group PLC - intellectual property commercialisation firm - Says portfolio company Cambridge Raman Imaging Ltd is now part of CRIMSON, an EUR5 million pan-European project to develop bio-photonic cell and tissue imaging technology to understand in greater depth the cellular origins of diseases.
"CRIMSON is looking to develop technology that could transform how biomedical researchers investigate the cellular origins of diseases, including cancer. Cambridge Raman Imaging's involvement in this prestigious project is strong validation of its expertise," Chief Executive Neil Crabb says.
Current stock price: 63.15 pence
Year-to-date change: down 5.0%
By Arvind Bhunjun; [email protected]
Copyright 2020 Alliance News Limited. All Rights Reserved.
Related Shares:
Frontier Ip